Tafasitamab Treatment Option Approved for Relapsed or Refractory Follicular Lymphoma in US
In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed or refractory follicular lymphoma (FL).
This combination includes tafasitamab (also known as Monjuvi®, developed by Incyte), rituximab, and lenalidomide — and is now available for eligible patients in the United States.
Upcoming Webinar: FLF Post-ICML Webinar – Charting Our Progress towards a Cure
Join us for an informative webinar where we discuss some of the key topics covered during our Satellite Symposium held in June 2025, at the 18th International Conference of Malignant Lymphoma (ICML) in Lugano.
The Power of Seed Funding: Accelerating Research in Follicular Lymphoma
One example of the impactful ways we advance our mission to cure follicular lymphoma (FL) is through our seed funding of the world-renowned Dana-Farber Cancer Institute.
FLF shines a spotlight on follicular lymphoma at 18-ICML
We are thrilled to announce that the FLF will be taking centre stage at the upcoming 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, from June 17th-21st, 2025.
Driving Breakthroughs in Follicular Lymphoma Research
At the Follicular Lymphoma Foundation (FLF), we’re funding bold, high-impact research to transform what it means to live with follicular lymphoma (FL). Guided by ongoing input from patients, we’re focused on accelerating progress toward cure.
Liso-Cel CAR-T cell therapy approved for relapsed/refractory follicular lymphoma in the EU and UK
In recent weeks there have been a number of announcements regarding an alternative treatment option now being available for adults with relapsed/ refractory indolent follicular lymphoma (FL) across the EU and transformed follicular lymphoma within the UK.
Two new ASPIRE awards target Biomarker Discovery in Follicular Lymphoma
The Mark Foundation for Cancer Research and the Follicular Lymphoma Foundation have joined forces to co-fund two new ASPIRE Awards focused on developing more personalized treatment strategies for FL.
Insights and Impact: The FLF at ASH Annual Meeting 2024, San Diego Â
The Follicular Lymphoma Foundation (FLF) was thrilled to participate in the recent American Society of Hematology (ASH) Annual Meeting.
Welcoming Emma France as FLF’s New Global CEO
The FLF welcomes Emma France as our new Global CEO. With over 20 years of non-profit leadership, Emma will help drive our mission forward with bold action and impactful change.
FLF’s CMO Shares Key Scientific Highlights from ASH 2024
FLF’s CMO highlights key takeaways from ASH 2024 on follicular lymphoma, from immunotherapy to new treatments.